MNTA Momenta Pharmaceuticals Inc

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Matt Ottmer as Chief Operating Officer. Mr. Ottmer will oversee the operational management of strategic product development, research, clinical development, pharmaceutical sciences and commercial activities. Mr. Ottmer will report directly to Craig Wheeler, Momenta’s President and Chief Executive Officer, and will serve as a member of the Executive Committee.

“Matt joins Momenta after a successful 16 year career at Biogen, Inc. where he was directly involved in the company’s global operations, business planning, organizational development and finances,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “Our team will greatly benefit from Matt’s deep cross-functional leadership and operations expertise as we continue to advance our biosimilar and novel drug programs toward commercialization in the coming years.”

Mr. Ottmer most recently served as Senior Vice President, Strategy & Emerging Businesses at Biogen, Inc. where he led cross-functional assessment, prioritization, and implementation planning across a broad range of value-creating opportunities including internal capability building, alliances and in-licenses, and mergers and acquisitions. Before his promotion to Senior Vice President, Mr. Ottmer held positions of increasing responsibility at Biogen from 1999 to 2015 including Head of Tysabri Business, Chief of Staff to the CEO, President of Syntonix Pharmaceuticals, Inc. (a wholly owned subsidiary of Biogen), and Vice President, Global Operations. He received a Bachelor of Arts degree in political science from the University of Michigan and a Master’s in Business Administration from Northwestern University’s Kellogg School of Management.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Mr. Ottmer improving efficiencies within the Company’s operations team and benefitting the Company.  Forward-looking statements may be identified by words such as "anticipate," "believe," "continue," "could," "hope," "target," "project," "goal," "objective," "guidance," "plan," "potential," "predict," "might," "estimate," "expect," "intend," "may," "seek", "should," "will," "would," "look forward" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com

MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com